Nuvalent Inc (NUVL)
70.35
-2.14
(-2.95%)
USD |
NASDAQ |
May 03, 16:00
70.34
-0.01
(-0.01%)
After-Hours: 20:00
Nuvalent Free Cash Flow (Quarterly): -30.21M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -30.21M |
| September 30, 2023 | -22.98M |
| June 30, 2023 | -22.14M |
| March 31, 2023 | -24.41M |
| December 31, 2022 | -17.78M |
| September 30, 2022 | -18.18M |
| June 30, 2022 | -15.48M |
| March 31, 2022 | -13.54M |
| Date | Value |
|---|---|
| December 31, 2021 | -12.96M |
| September 30, 2021 | -11.40M |
| June 30, 2021 | -9.712M |
| March 31, 2021 | -5.933M |
| December 31, 2020 | -4.937M |
| September 30, 2020 | -4.071M |
| June 30, 2020 | -2.946M |
| March 31, 2020 | -2.995M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-30.21M
Minimum
Dec 2023
-2.946M
Maximum
Jun 2020
-13.73M
Average
-13.25M
Median
Free Cash Flow (Quarterly) Benchmarks
| Geron Corp | -62.87M |
| Verastem Inc | -29.68M |
| Karyopharm Therapeutics Inc | -18.58M |
| Syndax Pharmaceuticals Inc | -41.35M |
| AnaptysBio Inc | -34.63M |